 SAN CARLOS, Calif., Jan. 06, 2022 GLOBE NEWSWIRE -- Iovance Biotherapeutics, Inc. NASDAQ: IOVA, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Fred Vogt, PhD, Esq., Interim Chief Executive Officer, President and General Counsel of Iovance, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30 a.m. ET. The live and archived webcasts of the presentation will be available in the Investors section of the Iovance website at 